Affordable CHOICE Act

HR7023, titled the Affordable CHOICE Act, was introduced on January 12, 2026 and referred to the House Committee on Energy and Commerce. It is in the earliest legislative stage with only 3 total actions (introduction and referral). The bill has 5 cosponsors, no text available, and no markups or hearings. There is a companion bill in the Senate (S3599), which provides some bipartisan interest but does not advance this bill out of committee by itself. The bill covers the Health policy area, meaning any eventual energy impact would be secondary to healthcare provisions. Based on the available data, there is no stated spending authorization, no direct procurement mandate, and no regulatory timeline that could affect any company's revenue or costs. The sponsor, Rep. Schakowsky, is a senior House member but not the committee chair, which reduces near-term passage odds. The legislative path requires full committee consideration, potential markup, floor vote in the House, Senate passage of the companion bill, conference committee reconciliation, and presidential action — all of which require significant time and political capital. Without bill text, the exact mechanisms for consumer health choice (implied by the title) remain unknown. No publicly traded company faces a direct and measurable financial impact at this stage. The established confidence gate of 0.65 for inclusion of any ticker is not met.